An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status:
Completed
Trial end date:
2018-04-26
Target enrollment:
Participant gender:
Summary
The main purposes of this study are to see if it is safe to use a new medication called
vamorolone for more than two weeks in children with Duchenne muscular dystrophy (DMD), to see
if vamorolone works for the treatment for DMD, and to see how any potential side effects
compare to those seen in boys using steroids.
Phase:
Phase 2
Details
Lead Sponsor:
ReveraGen BioPharma, Inc.
Collaborators:
Cooperative International Neuromuscular Research Group National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Neurological Disorders and Stroke (NINDS) University of Pittsburgh